ALMR
SellHot AirAlamar Biosciences, Inc. · Healthcare · United States · $2.1B cap · $22.6M/day traded
$30.69 +3.3% · close 23 Oct · scored 24 Oct
Hot Air: Rising on momentum alone: weak business, rich price.
As of 24 Oct 2026, MoatMap's StockRank for Alamar Biosciences, Inc. (ALMR) is 32/100, ranked against 24,000+ stocks in 35 markets (Quality 41, Value 24, Momentum 56, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT ALAMAR BIOSCIENCES, INC.
Read
Alamar Biosciences, Inc. is a life sciences company developing advanced proteomics technologies designed for the early detection and treatment of cancer and inflammatory diseases. The company's proprietary NULISA and Attobody platforms enable ultra-high sensitivity protein detection, overcoming limitations of traditional assays. Its competitive moat is anchored by its cutting-edge molecular detection technology and its potential to revolutionize liquid biopsy and biomarker research.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 25.1M | 74.2M | 100.4M | 118.6M | 165.7M | 49.4% |
| EPS | -0.71 | -0.45 | -1.20 | -1.10 | -0.45 | — |
| Shares | 66.5M | 66.5M | 69.4M | — | — | — |
| Debt | 33.1M | 41.5M | 51.4M | — | — | — |
| Equity | -133.4M | -159.0M | — | — | — | — |
| Op CF | -55.2M | -53.6M | -60.3M | — | — | — |
| Inv CF | -53.9M | 46.2M | — | — | — | — |
| Fin CF | 113.4M | 10.8M | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALMR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALMR | Alamar Biosciences, Inc.(you) | $2.1B | 32 | Sell |
| TMDX | TransMedics Group, Inc. | $2.5B | 33 | Sell |
| BFLY | Butterfly Network, Inc. | $1.8B | 29 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.7B | 36 | Hold |
| AXGN | Axogen, Inc. | $2.2B | 43 | Hold |
| ESTA | Establishment Labs Holdings Inc. | $1.9B | 21 | Sell |
| AORT | Artivion, Inc. | $1.1B | 35 | Hold |
| CBLL | CeriBell, Inc. | $1.0B | 33 | Sell |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 37 | Hold |
| IRTC | iRhythm Holdings, Inc. | $4.0B | 37 | Hold |
Peer medians: ROE -31.0% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.